Literature DB >> 25469453

The effect of different doses of near infrared light on dopaminergic cell survival and gliosis in MPTP-treated mice.

Nabil El Massri1, Daniel M Johnstone2, Cassandra L Peoples1, Cécile Moro3, Florian Reinhart3, Napoleon Torres3, Jonathan Stone2, Alim-Louis Benabid3, John Mitrofanis1.   

Abstract

We have used the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model to explore whether (i) the neuroprotective effect of near infrared light (NIr) treatment in the SNc is dose-dependent and (ii) the relationship between tyrosine hydroxylase (TH)+ terminal density and glial cells in the caudate-putamen complex (CPu). Mice received MPTP injections (50 mg/kg) and 2 J/cm2 NIr dose with either 2 d or 7 d survival period. In another series, with a longer 14 d survival period, mice had a stronger MPTP regime (100 mg/kg) and either 2 J/cm2 or 4 J/cm2 NIr dose. Brains were processed for routine immunohistochemistry and cell counts were made using stereology. Our findings were that in the 2 d series, no change in SNc TH+ cell number was evident after any treatment. In the 7 d series however, MPTP insult resulted in ∼45% reduction in TH+ cell number; after NIr (2 J/cm2) treatment, many cells were protected from the toxic insult. In the 14 d series, MPTP induced a similar reduction in TH+ cell number. NIr mitigated the loss of TH+ cells, but only at the higher dose of 4 J/cm2; the lower dose of 2 J/cm2 had no neuroprotective effect in this series. The higher dose of NIr, unlike the lower dose, also mitigated the MPTP- induced increase in CPu astrocytes after 14 d; these changes were independent of TH+ terminal density, of which, did not vary across the different experimental groups. In summary, we showed that neuroprotection by NIr irradiation in MPTP-treated mice was dose-dependent; with increasing MPTP toxicity, higher doses of NIr were required to protect cells and reduce astrogliosis.

Entities:  

Keywords:  neuroprotection; substantia nigra; tyrosine hydroxylase

Mesh:

Substances:

Year:  2015        PMID: 25469453     DOI: 10.3109/00207454.2014.994063

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.590


  17 in total

1.  Photobiomodulation-induced changes in a monkey model of Parkinson's disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum.

Authors:  Nabil El Massri; Ana P Lemgruber; Isobel J Rowe; Cécile Moro; Napoleon Torres; Florian Reinhart; Claude Chabrol; Alim-Louis Benabid; John Mitrofanis
Journal:  Exp Brain Res       Date:  2017-03-15       Impact factor: 1.972

Review 2.  Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends.

Authors:  Namgue Hong
Journal:  Biomed Eng Lett       Date:  2019-06-12

3.  No evidence for toxicity after long-term photobiomodulation in normal non-human primates.

Authors:  Cécile Moro; Napoleon Torres; Katerina Arvanitakis; Karen Cullen; Claude Chabrol; Diane Agay; Fannie Darlot; Alim-Louis Benabid; John Mitrofanis
Journal:  Exp Brain Res       Date:  2017-07-25       Impact factor: 1.972

Review 4.  Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases.

Authors:  Silvia Lima Costa; Victor Diogenes Amaral Silva; Cleide Dos Santos Souza; Cleonice Creusa Santos; Irmgard Paris; Patricia Muñoz; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2016-03-07       Impact factor: 3.911

5.  Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease.

Authors:  Seyma Bahdoudi; Ikram Ghouili; Mansour Hmiden; Jean-Luc do Rego; Benjamin Lefranc; Jérôme Leprince; Julien Chuquet; Jean-Claude do Rego; Ann-Britt Marcher; Susanne Mandrup; Hubert Vaudry; Marie-Christine Tonon; Mohamed Amri; Olfa Masmoudi-Kouki; David Vaudry
Journal:  Cell Mol Life Sci       Date:  2017-12-20       Impact factor: 9.261

Review 6.  Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.

Authors:  Song Li; Jie Dong; Cheng Cheng; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2016-08-11       Impact factor: 3.575

Review 7.  Current application and future directions of photobiomodulation in central nervous diseases.

Authors:  Muyue Yang; Zhen Yang; Pu Wang; Zhihui Sun
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

8.  Near-infrared light (670 nm) reduces MPTP-induced parkinsonism within a broad therapeutic time window.

Authors:  Florian Reinhart; Nabil El Massri; Daniel M Johnstone; Jonathan Stone; John Mitrofanis; Alim-Louis Benabid; Cécile Moro
Journal:  Exp Brain Res       Date:  2016-02-15       Impact factor: 2.064

9.  Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys.

Authors:  Nabil El Massri; Cécile Moro; Napoleon Torres; Fannie Darlot; Diane Agay; Claude Chabrol; Daniel M Johnstone; Jonathan Stone; Alim-Louis Benabid; John Mitrofanis
Journal:  Exp Brain Res       Date:  2016-07-05       Impact factor: 2.064

Review 10.  Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease.

Authors:  Daniel M Johnstone; Cécile Moro; Jonathan Stone; Alim-Louis Benabid; John Mitrofanis
Journal:  Front Neurosci       Date:  2016-01-11       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.